Momentum Indicators for Biotech Equities - PDL BioPharma, Geron, Celldex Therapeutics, XOMA Corp., and Juno Therapeutics

LONDON, February 9, 2015 /PRNewswire/ --

Investor-Edge has initiated coverage on the following equities: PDL BioPharma Inc. (NASDAQ: PDLI), Geron Corporation (NASDAQ: GERN), Celldex Therapeutics Inc. (NASDAQ: CLDX), XOMA Corporation (NASDAQ: XOMA), and Juno Therapeutics Inc. (NASDAQ: JUNO). Free research report on PDL BioPharma can be accessed at http://get.Investor-Edge.com/pdf/?c=PDL%20BioPharma&d=09-Feb-2015&s=PDLI. On Friday, February 06, 2015, the NASDAQ Composite ended at 4,744.40, down 0.43%, the Dow Jones Industrial Average declined 0.34%, to finish the day at 17,824.29, and the S&P 500 closed at 2,055.47, down 0.34%. The losses were broad based as eight out of ten sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 806.81, down 0.84%, while the index has advanced 4.07% in the last three months. Register for your complimentary reports at the links given below.  

PDL BioPharma Inc.'s stock edged 0.28% higher, to close the day at $7.22. The stock recorded a trading volume of 1.85 million shares, below its three months average volume of 2.70 million shares. The stock oscillated between $7.20 and $7.32 during the session. Over the last three trading sessions and over the past one month, PDL BioPharma Inc.'s shares have fallen by 0.96% and 2.04%, respectively. Further, the stock has lost 13.95% in the previous year. The company is trading below its 50-day and 200-day moving averages. PDL BioPharma Inc.'s 200-day moving average of $8.58 is above its 50-day moving average of $7.61. Additionally, the stock traded at a PE ratio of 3.64 and has a Relative Strength Index (RSI) of 39.58. Sign up and read the free notes on PDLI at:

http://get.Investor-Edge.com/pdf/?c=PDL%20BioPharma&d=09-Feb-2015&s=PDLI

On Friday, shares in Geron Corp. recorded a trading volume of 1.39 million shares, lower than its three months average volume of 4.54 million shares. The stock ended the day at $3.03, which was 1.47% below its previous day's closing of $3.07, and registered an intraday range of $3.00 and $3.14. Although Geron Corp.'s shares have surged 29.83% in the previous three months, it has lost 2.73% in the last three trading sessions and 33.16% in the past one year. The company is trading above its 200-day moving average of $2.58. Furthermore, shares of Geron Corp. have an RSI of 42.54. The complimentary notes on GERN can be downloaded as in PDF format at:

http://get.Investor-Edge.com/pdf/?c=Geron&d=09-Feb-2015&s=GERN

Celldex Therapeutics Inc.'s stock lost 1.27%, to close Friday's session at $19.50, after oscillating between $19.15 and $20.00. The stock recorded a trading volume of 1.16 million shares, below its three months average volume of 2.91 million shares. Over the last one month and the previous three months, Celldex Therapeutics Inc.'s shares have advanced 3.50% and 45.31%, respectively. However, the stock has declined 23.08% in the last one year. The company is trading above its 50-day and 200-day moving averages. The stock's 50-day moving average of $19.45 is above its 200-day moving average of $16.00. Further, Celldex Therapeutics Inc.'s stock has an RSI of 45.03. Register for free on Investor-Edge and access the latest research on CLDX at:

http://get.Investor-Edge.com/pdf/?c=Celldex%20Therapeutics&d=09-Feb-2015&s=CLDX

XOMA Corp.'s stock finished Friday's session 0.87% lower at $3.41. A total of 1.31 million shares were traded, which was below its three months average volume of 2.87 million shares. The stock moved between $3.35 and $3.49 during the session. XOMA Corp.'s shares have declined 2.85% in the previous three trading sessions and 6.83% in the last one month. Additionally, the stock has lost 53.48% in the past one year. The company's shares are trading below their 50-day and 200-day moving averages. Moreover, the stock's 200-day moving average of $4.19 is greater than its 50-day moving average of $4.03. XOMA Corp.'s stock has an RSI of 39.88. The complete research on XOMA is available for free at:

http://get.Investor-Edge.com/pdf/?c=XOMA%20Corp.&d=09-Feb-2015&s=XOMA

On Friday, shares in Juno Therapeutics Inc. fluctuated between $39.40 and $41.89 before ending the session 4.15% lower at $39.45. The stock reported a trading volume of 0.93 million shares during the session. Juno Therapeutics Inc.'s shares have declined 4.27% in the previous three trading sessions and 25.23% in the last one month. Moreover, shares of Juno Therapeutics Inc. have an RSI of 50.04. Free in depth research on JUNO is available at:

http://get.Investor-Edge.com/pdf/?c=Juno%20Therapeutics&d=09-Feb-2015&s=JUNO

About Investor-Edge.com 

At Investor-Edge, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Investor-Edge comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.

===============

EDITOR'S NOTES:

===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] www.investor-edge.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] www.investor-edge.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] www.investor-edge.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-Edge, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Investor-Edge in this article or report according to the procedures outlined by Investor-Edge. Investor-Edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Investor-Edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Investor-Edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-Edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-Edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-Edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Investor-Edge

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED